The advent of neoadjuvant chemotherapy (NAC) prior to surgery and immune checkpoint therapy (ICT) have revolutionized bladder cancer management1-7. However, stratification of patients that would benef
(A) High signature score correlates with Ktrans improvement in the treatment arm and Ktrans deterioration in the placebo arm. Scatter plots show baseline and treatment adjusted 14-week change in log K
TP53 mutation is a critical driver mutation that affects the carcinogenesis and prognosis of patients with pancreatic cancer (PC). Currently, there is no driver mutation-derived signature based on TP5
ANOVA test, significant values (p<0.05) are in bold. Smoking, co-morbidity, ACPA and RF variables are defined as presence or absence; dietary habits variable is defined as mediterranean diet or non-me
